Asterias Biotherapeutics Inc (NYSE:AST) Short Interest Up 7.8% in July

Asterias Biotherapeutics Inc (NYSE:AST) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 2,635,157 shares, an increase of 7.8% from the July 14th total of 2,444,930 shares. Based on an average daily trading volume, of 181,807 shares, the short-interest ratio is presently 14.5 days. Approximately 9.8% of the company’s stock are sold short.

Several brokerages have recently commented on AST. Zacks Investment Research raised Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Monday, July 17th. HC Wainwright set a $12.00 target price on Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 11th.

Shares of Asterias Biotherapeutics (NYSE:AST) traded up 1.67% during mid-day trading on Friday, hitting $3.05. The stock had a trading volume of 147,881 shares. The stock’s market capitalization is $152.43 million. Asterias Biotherapeutics has a 12-month low of $2.54 and a 12-month high of $5.80. The stock’s 50-day moving average price is $3.41 and its 200-day moving average price is $3.40.

Asterias Biotherapeutics (NYSE:AST) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%. The company had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.25 million. On average, equities analysts anticipate that Asterias Biotherapeutics will post ($0.64) EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Family Management Corp increased its position in Asterias Biotherapeutics by 15.6% in the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock worth $168,000 after buying an additional 6,416 shares in the last quarter. California State Teachers Retirement System increased its position in Asterias Biotherapeutics by 4.6% in the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,100 shares in the last quarter. Teachers Advisors LLC increased its position in Asterias Biotherapeutics by 13.1% in the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock worth $206,000 after buying an additional 6,714 shares in the last quarter. Finally, State Street Corp increased its position in Asterias Biotherapeutics by 24.1% in the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 63,773 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/asterias-biotherapeutics-inc-nyseast-short-interest-update-updated.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply